Aspira Pathlab & Diagnostics Ltd (ASPIRA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aspira Pathlab & Diagnostics Ltd on NSE and BSE, with an AI summary of each filing.
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Un-audited Financial ....
Intimation · 06 Nov 2026, 5:30 am
Aspira Pathlab & Diagnostics Schedules Board Meeting for Q2 FY27 Results Aspira Pathlab & Diagnostics Limited announced that its Board of Directors will meet on 6th Nov'26 to consider and approve the un-audited standalone financial results, alongside the limited review report, for the second quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives until 48 hours following the declaration of the financial results.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 01 Oct 2026, 3:56 pm
Promoter Jay Arvind Bhanushali Acquires Shares in Aspira Pathlab & Diagnostics Promoter Jay Arvind Bhanushali acquired 245 equity shares (0.002% voting capital) of Aspira Pathlab & Diagnostics Ltd via open market purchases on 28th Sep'26. Following the transaction, Bhanushali's direct shareholding increased from 7,49,262 equity shares to 7,49,507 equity shares, maintaining a 7.28% stake in the total voting and diluted share capital. The company’s overall equity base remains unchanged at 1,02,93,000 equity shares of Rs. 10 each, aggregating to Rs. 10.29 crore.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 28 Sept 2026, 3:56 pm
Jay Arvind Bhanushali Increases Stake in Aspira Pathlab & Diagnostics Promoter Jay Arvind Bhanushali acquired 1,424 equity shares (0.01% stake) of Aspira Pathlab & Diagnostics Ltd via open market transactions between 17th Sep'26 and 24th Sep'26. Following this transaction, his equity holding in the company increased from 7,47,838 shares (7.27%) to 7,49,262 shares (7.28%). The company's total voting capital remains unchanged at Rs 10.29 crore, divided into 1.03 crore equity shares of Rs 10 each.
Disclosure of Voting Results of 53rd Annual General Meeting along with the Scrutinizer Report
Annual General Meeting · 26 Sept 2026, 12:36 am
Please find attached summary of proceeding /outcome of the 53rd Annual General Meeting of the Company held on Friday,25th September,2026
Annual General Meeting · 26 Sept 2026, 12:29 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 16 Sept 2026, 11:41 pm
Promoter Jay Arvind Bhanushali Increases Stake in Aspira Pathlab & Diagnostics Jay Arvind Bhanushali, a promoter of Aspira Pathlab & Diagnostics Ltd, acquired 1,387 equity shares (0.013% stake) via open market transactions between 11th Sep'26 and 16th Sep'26. Following the acquisition, the promoter's total holding increased from 7,46,451 equity shares (7.25%) to 7,47,838 equity shares (7.27% of total voting capital). The company's total equity share capital remains unchanged at Rs 10.29 cr, divided into 1,02,93,000 equity shares of Rs 10 each.
Enclosed herewith Constitution of Right Issue Committee for proposed right issue
Others (Uncategorized) · 12 Sept 2026, 10:27 pm
Aspira Pathlab Board Approves Rights Issue of Up to Rs 65 Crore Aspira Pathlab & Diagnostics' Board approved a fundraise of up to Rs 65.00 cr via a Rights Issue of equity or convertible instruments to eligible shareholders on 12th Sep'26, subject to shareholder and regulatory approvals. The Board constituted a Rights Issue Committee—chaired by Nikunj Velji Mange—to finalize the record date, issue price, entitlement ratio, and appointment of intermediaries.
Intimation under Regulation 30 (LODR) -Raising of Funds
Others (Uncategorized) · 12 Sept 2026, 10:22 pm
Aspira Pathlab Board Approves Rights Issue Up to Rs 65 Crore Aspira Pathlab & Diagnostics' Board approved fundraising of up to Rs 65.00 crore via a rights issue of equity shares or convertible instruments to eligible shareholders on 12th Sep'26. The issue remains subject to shareholder and regulatory approvals. Additionally, the Board constituted a Rights Issue Committee, chaired by Nikunj Velji Mange, to finalize key terms, including the issue price, entitlement ratio, record date, and appointment of intermediaries.
The Board of Directors of the Company in its meeting held on 12th September, 2026 have considered and approved the following matters; 1) To raise Fund for an amount not exceeding Rs. 65,00,00,000/- ....
Outcome · 12 Sept 2026, 10:18 pm
Aspira Pathlab Approves Rights Issue to Raise Up to Rs 65 Crore Aspira Pathlab & Diagnostics' Board approved a fundraise of up to Rs 65 crore via a Rights Issue of equity shares or other convertible instruments on 12th Sep'26, subject to shareholder and regulatory approvals. The Board constituted a Rights Issue Committee, chaired by Nikunj Velji Mange, to finalize issue terms, including the record date, issue price, and rights entitlement ratio.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 12 Sept 2026, 6:50 pm
Aspira Pathlab & Diagnostics: Promoter Jay Arvind Bhanushali Acquires Additional Shares Promoter Jay Arvind Bhanushali disclosed an open-market acquisition of 74 equity shares (0.00% voting capital) in Aspira Pathlab & Diagnostics Ltd on 10th Sep'26. Following the transaction, Bhanushali's total shareholding marginally increased from 7,46,377 equity shares to 7,46,451 equity shares, while the total voting share capital remained steady at 7.25%. The company's total equity share capital stands at Rs 10,29,30,000, divided into 1,02,93,000 equity shares of Rs 10 each.
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/09/2026 ,inter alia, to consider and approve To consider approve ....
Intimation · 07 Sept 2026, 7:15 pm
Aspira Pathlab & Diagnostics Board to Consider Fundraising on 12th Sep'26 Aspira Pathlab & Diagnostics Limited has scheduled a Board of Directors meeting for 12th Sep'26 to evaluate and approve fundraising proposals. The capital raise is contemplated via the issuance of equity shares, convertible warrants, or other permissible instruments through preferential issue, private placement, rights issue, or other eligible methods, subject to requisite shareholder and statutory approvals.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 05 Sept 2026, 5:22 pm
Jay Arvind Bhanushali Acquires Stake in Aspira Pathlab & Diagnostics Promoter Jay Arvind Bhanushali acquired 623 equity shares (0.0060% stake) of Aspira Pathlab & Diagnostics Ltd through open market purchases on 2nd Sep'26. Following the transaction, his holding marginally increased from 7,45,754 shares (7.25%) to 7,46,377 shares (7.25%) of the total equity base. The company's total voting capital remains unchanged at ₹10,29,30,000, comprising 1,02,93,000 equity shares of ₹10 each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 03 Sept 2026, 3:54 pm
Pursuant to Regulation 36 (1)(b) of SEBI (LODR)2015, The Company has dispatched letter containing weblink of Annual Report for Financial year 2025-26
Annual Report · 01 Sept 2026, 10:31 pm
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Notice of ....
Others (Uncategorized) · 01 Sept 2026, 12:14 am
Intimation of Notice of 53rd Annual General Meeting for the Financial Year 2025-26
Annual General Meeting · 31 Aug 2026, 11:42 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali
Acquisition/ Disposal of Shares · 28 Aug 2026, 4:33 pm
1. Board approved the appointment of Mr. Vaibhav Odhekar as Additional Executive Director with immediate Effect. 2. Board Approved the regularization of Mr. Vaibhav Odhekar as Executive ....
Change in Management · 12 Aug 2026, 10:21 pm
Unaudited Standalone Financial Results for quarter ended 30 June 2026
Financial Result · 12 Aug 2026, 10:10 pm
Aspira Pathlab Q1FY27 Results, Management Changes, and Deferred Fundraising Aspira Pathlab reported a net loss of ₹3.77 lakhs for Q1FY27, ending Jun 30, '26, a sharp decline from a ₹46.94 lakhs profit YoY. Revenue from operations grew 17.5% YoY to ₹616.91 lakhs, but total expenses rose 29.5% to ₹632.62 lakhs. The board approved Q1 results, appointed Vaibhav Odhekar as Additional Executive Director, and re-designated Nikunj Velji Mange as Managing Director. A proposal for fundraising was considered but ultimately deferred, with no decision taken at the meeting.
Outcome of Board Meeting held on 12th August 2026
Outcome · 12 Aug 2026, 10:00 pm
Aspira Pathlab & Diagnostics Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 617 (+17.6% YoY | -5.4% QoQ) ■ EBITDA: 34.4 (-58.1% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 5.6 (-1007 bps YoY | Loss to Profit QoQ) ■ PAT: -3.8 (Profit to Loss YoY | +94.5% QoQ) ■ EPS (INR): -0.04 (Profit to Loss YoY | +94.0% QoQ)
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....
Intimation · 12 Aug 2026, 5:30 am
Aspira Pathlab Board Meeting on Aug 12, 2026, to Consider Q1 Results and Fundraising Aspira Pathlab & Diagnostics' Board of Directors will meet on Aug 12, '26, to consider and approve the un-audited standalone financial results for the quarter ended Jun 30, '26. The board will also evaluate and potentially approve a proposal for fundraising. This may involve issuing equity shares or convertible warrants through methods such as preferential issue, private placements, or a rights issue, subject to necessary shareholder and statutory approvals. Other incidental matters will also be on the agenda.
Enclosed herewith Resignation of M/s Vishal J Bhanushali and Associated with effect from 13th August 2026
Change in Auditor · 03 Aug 2026, 10:36 pm
Aspira Pathlab & Diagnostics: Internal Auditor Resigns Aspira Pathlab & Diagnostics announced that its Internal Auditor, M/s. Vishal J Bhanushali and Associates, has resigned effective 13th Aug'26. The company stated the reason for the resignation was "preoccupation and other personal reasons." This key personnel change was communicated to the BSE on 03rd Aug'26 in compliance with SEBI LODR regulations.
Enclosed herewith Resignation of Mr. Pankaj Jashwant Shah from post of Managing Director and Chief Executive Officer with effect from 03.08.2026
Change in Management · 03 Aug 2026, 10:28 pm
Aspira Pathlab MD & CEO Pankaj Jashwant Shah Resigns Aspira Pathlab & Diagnostics announced the resignation of Mr. Pankaj Jashwant Shah from his positions as Managing Director and Chief Executive Director, effective 03 Aug'26. The company stated the reason for the departure as personal. The resignation notice was filed with the exchange under Regulation 30 of SEBI LODR. No further details regarding succession or strategic impact were disclosed in the filing.
Enclosed herewith Resignation of Mr. Pankaj Jashwant Shah from post of Managing Director cum Chief Executive Officer with effect from 03.08.2026
Change in Management · 03 Aug 2026, 10:25 pm
Aspira Pathlab MD & CEO Pankaj Jashwant Shah Resigns Aspira Pathlab & Diagnostics announced the resignation of Mr. Pankaj Jashwant Shah from his positions as Managing Director and Chief Executive Director, effective 03 Aug'26. The company stated the reason for the departure as "personal reasons" in its regulatory filing. This leadership change represents a significant development for the company's top management structure. No other material details regarding the transition or succession plan were provided in the disclosure.
Enclosed herewith Resignation of Pankaj jashwant Shah (DIN:02836324)
Change in Management · 03 Aug 2026, 10:16 pm
Aspira Pathlab MD & CEO Pankaj Shah Resigns Aspira Pathlab & Diagnostics announced that Mr. Pankaj Jashwant Shah (DIN: 02836324) has resigned from his position as Managing Director and Chief Executive Director. The resignation, tendered for personal reasons, is effective from 03 Aug'26. This key leadership change is a material event for the company, potentially impacting its strategic direction and operational management. The company confirmed there are no other material disclosures or relationships to report in connection with the cessation.